Partner Nate Lacktman was quoted in a Modern Healthcare article, “Tapping Telehealth for Complex Cases,” which covers how physicians are beginning to utilize telehealth capabilities to offer remote assistance for high-acuity patients. The article discusses telehealth’s positive effects on low-acuity patients thanks to direct-to-consumer telehealth platforms and explores the potential for the service to move into the high-acuity space.
Lacktman was quoted saying that direct-to-consumer companies “have done a good job of expanding access to low-acuity care. But health systems are well-positioned to use technology to care for the ‘sickest of the sick’ who account for the greatest share of healthcare spending.” He pointed out that the health system to “crack that nut … will be a game-changer.”
Lacktman was quoted saying that direct-to-consumer companies “have done a good job of expanding access to low-acuity care. But health systems are well-positioned to use technology to care for the ‘sickest of the sick’ who account for the greatest share of healthcare spending.” He pointed out that the health system to “crack that nut … will be a game-changer.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”